MCM6 as a Better Survival Predictor in Mantle Cell Lymphoma
Author Information
Author(s): Schrader C, Janssen D, Klapper W, Siebmann J-U, Meusers P, Brittinger G, Kneba M, Tiemann M, Parwaresch R
Primary Institution: University Hospital of Schleswig-Holstein, Campus Kiel
Hypothesis
Minichromosome maintenance protein 6 (MCM6) is a superior proliferation marker compared to Ki-67 and can predict survival in mantle cell lymphoma (MCL).
Conclusion
High levels of MCM6 expression indicate a shorter overall survival in patients with mantle cell lymphoma.
Supporting Evidence
- MCM6 expression levels ranged from 12.0 to 95.6%, with a mean of 61.0%.
- MCM6 was significantly higher than Ki-67 expression (mean 19.8%).
- Patients with MCM6 expression over 75% had a median survival of only 16 months.
- Multivariate analysis showed MCM6 as an independent predictor of survival.
Takeaway
This study found that a protein called MCM6 can help doctors predict how long patients with a type of blood cancer called mantle cell lymphoma might live, and it works better than another common marker called Ki-67.
Methodology
Immunohistochemical analysis of lymph node biopsy specimens from 70 patients with mantle cell lymphoma to assess MCM6 expression levels.
Limitations
The study did not analyze MCM2 expression in relation to clinical data.
Participant Demographics
Patients were previously untreated with a diagnosis of mantle cell lymphoma.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website